

---

**From:** Adam Brosius[adam@pharmasales.com]  
**Sent:** Fri 4/16/2021 11:36:25 AM (UTC)  
**To:** Pat Boyd[PatB@Safechain.com]; Garrett Mellott[garrett@pharmasales.com]  
**Subject:** Fwd: PED  
**Attachment:** BIKTARVY 2.pdf

take a look lets chat about these privately

**Worldwide Pharma Sales Group Inc.**

**455 NE Fifth Avenue Suite D434**

**Delray Beach, Florida 33483**

**215.595.3932**

**[adam@pharmasales.com](mailto:adam@pharmasales.com)**

----- Forwarded message -----

From: **CM PHARMA** <[cm.pharma@yahoo.com](mailto:cm.pharma@yahoo.com)>

Date: Thu, Apr 15, 2021 at 9:43 PM

Subject: PED

To: Adam Brosius <[adam@pharmasales.com](mailto:adam@pharmasales.com)>

GOVERNMENT  
EXHIBIT

**272**

1:24-cr-20255-WPD

## Drug Supply Chain Security Act Document Doc#00000024017

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <b>5599</b>
NDC: <b>61958-2501-01</b>	CustomerPO #: <b>-</b>
	Document Type: <b>Invoice</b>
	Reference Date: <b>4/7/2021</b>

LOT # CDSFGA	QUANTITY 3	EXP DATE 01/23
LOT # CFBGGA	QUANTITY 3	EXP DATE 02/23
LOT # 023776	QUANTITY 2	EXP DATE 04/23

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY 60706408</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY 60706408</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
--	--

<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
--	--

<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CHESAPEAKE DR</b> <b>CAMBRIDGE MD 21613</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CHESAPEAKE DR</b> <b>CANBRIDGE MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>
---	---

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;  
(B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;  
(C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;  
(D) did not knowingly ship a suspect or illegitimate product;  
(E) had systems and processes in place to comply with verification requirements under section 582;  
(F) did not knowingly provide false transaction information; and  
(G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024018

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <u><b>5599</b></u>
NDC: <b>61958-2501-01</b>	CustomerPO #: <u>-</u>
	Document Type: <u><b>Invoice</b></u>
	Reference Date: <u><b>4/7/2021</b></u>

LOT # 020730	QUANTITY 3	EXP DATE 01/23
LOT# 021347	QUANTITY 2	EXP DATE 02/23
LOT # 025976	QUANTITY 3	EXP DATE 05/23

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE MD 21613</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

## Drug Supply Chain Security Act Document Doc#00000024019

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <b>5599</b>
NDC: <b>61958-2501-01</b>	CustomerPO #: <b>-</b>
	Document Type: <b>Invoice</b>
	Reference Date: <b>4/7/2021</b>

LOT # CDSFKA	QUANTITY 3	01/23
LOT # CFBGHA	QUANTITY 2	02/23
LOT# CDFXYA	QUANTITY 3	08/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021</b> <b>1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021</b> <b>1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021</b> <b>5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021</b> <b>5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE MD 21613</b> Date Purchased & Ref : <b>4/8/21</b> <b>1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE MD 21613</b> Date Received & Ref : <b>4/8/21</b> <b>1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;  
(B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;  
(C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;  
(D) did not knowingly ship a suspect or illegitimate product;  
(E) had systems and processes in place to comply with verification requirements under section 582;  
(F) did not knowingly provide false transaction information; and  
(G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024020

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <b>5599</b>
NDC: <b>61958-2501-01</b>	CustomerPO #: <b>-</b>
	Document Type: <b>Invoice</b>
	Reference Date: <b>4/7/2021</b>

LOT # 020729	QUANTITY 2	EXP DATE 01/23
LOT #020732	QUANTITY 1	EXP DATE 02/23
LOT # CDGWYA	QUANTITY 3	EXP DATE09/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021</b> <b>1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021</b> <b>1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021</b> <b>5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021</b> <b>5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21</b> <b>1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21</b> <b>1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024021

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <u><b>5599</b></u>
NDC: <b>61958-2501-01</b>	CustomerPO #: <u>-</u>
	Document Type: <u><b>Invoice</b></u>
	Reference Date: <u><b>4/7/2021</b></u>

LOT # CDVWGA	QUANTITY 2	EXP DATE 01/23
LOT # 021346	QUANTITY 1	EXP DATE 02/23
LOT # CDFYBA	QUANTITY 2	EXP DATE 09/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address <b>822 CAMBRIDGE, MD 21613:</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024022

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <u>5599</u>
NDC: <b>61958-2501-01</b>	CustomerPO #: <u>-</u>
	Document Type: <u>Invoice</u>
	Reference Date: <u>4/7/2021</u>

LOT # 020728	QUANTITY 2	EXP DATE 01/23
LOT # 021349	QUANTITY 1	EXP DATE 02/23
LOT # CDFYFA	QUANTITY 1	EXP Date 09/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024023

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>		ReferenceNumber: <b>5599</b>
NDC: <b>61958-2501-01</b>		CustomerPO #: <b>-</b>
		Document Type: <b>Invoice</b>
		Reference Date: <b>4/7/2021</b>

Lot # 020731	QUANTITY 2	EXP DATE 01/23
LOT# 022617	QUANTITY 6	EXP DATE 03/23
LOT# CDFYDA	QUANTITY 1	EXP DATE09/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.



# Drug Supply Chain Security Act Document Doc#00000024024

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <u><b>5599</b></u>
NDC: <b>61958-2501-01</b>	CustomerPO #: <u>-</u>
	Document Type: <u><b>Invoice</b></u>
	Reference Date: <u><b>4/7/2021</b></u>

LOT # CDSFHA	QUANTITY 2	EXP D ATE 01/23
LOT# CFBGPA	QUANTITY 4	EXP DATE 03/23
LOT # CDMGTA	QUANTITY 1	EXP DA TE 10/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIOND</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

## Drug Supply Chain Security Act Document Doc#00000024025

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <b>5599</b>
NDC: <b>61958-2501-01</b>	CustomerPO #: <b>-</b>
	Document Type: <b>Invoice</b>
	Reference Date: <b>4/7/2021</b>

LOT# 020727	QUANTITY 1	EXP DATE 01/23
LOT# 023255	QUANTITY 2	EXP DATE 03/23
LOT # 022054	QUANTITY 1	EXP DATE 11/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021</b> <b>1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021</b> <b>1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021</b> <b>5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021</b> <b>5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21</b> <b>1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21</b> <b>1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;  
(B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;  
(C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;  
(D) did not knowingly ship a suspect or illegitimate product;  
(E) had systems and processes in place to comply with verification requirements under section 582;  
(F) did not knowingly provide false transaction information; and  
(G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024026

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <u><b>5599</b></u>
NDC: <b>61958-2501-01</b>	CustomerPO #: <u>-</u>
	Document Type: <u><b>Invoice</b></u>
	Reference Date: <u><b>4/7/2021</b></u>

LOT # CDVWFB	QUANTITY 1	EXP DATE 01/23
LOT # 022616	QUANTITY 2	EX P DATE 03/23
LOT # 022057	QUANTITY 4	EXP DATE 12/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021</b> <b>1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021</b> <b>1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021</b> <b>5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021</b> <b>5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21</b> <b>1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21</b> <b>1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024027

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <u><b>5599</b></u>
NDC: <b>61958-2501-01</b>	CustomerPO #: <u>-</u>
	Document Type: <u><b>Invoice</b></u>
	Reference Date: <u><b>4/7/2021</b></u>

LOT # 020734	QUANTITY 4	EXP DA TE 02/23
LOT # 022619	QUANTITY 1	EXP DATE 03/23
LOT # 022053	QUANTITY 2	EX P DATE 12/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024028

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>		ReferenceNumber: <u>5599</u>
NDC: <b>61958-2501-01</b>		CustomerPO #: <u>-</u>
		Document Type: <u>Invoice</u>
		Reference Date: <u>4/7/2021</u>

LOT # 020733	QUANTITY 4	EXP DATE 02/23
LOT# 023774	QUANTITY 1	EXP DATE 03/23
LOT # CDSFCA	QUANTITY 2	EXP DATE 12/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
 Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021</b> <b>1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021</b> <b>1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021</b> <b>5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021</b> <b>5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21</b> <b>1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024029

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>		ReferenceNumber: <b>5599</b>
NDC: <b>61958-2501-01</b>		CustomerPO #: <b>-</b>
		Document Type: <b>Invoice</b>
		Reference Date: <b>4/7/2021</b>

LOT # 021348	QUANTITY 3	EXP DATE 02/23
LOT # 023254	QUANTITY 1	EXP DATE 03/23
LOT # CDSFFA	QUANTITY 1	EXP DATE 12/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

## Drug Supply Chain Security Act Document Doc#00000024030

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <b>5599</b>
NDC: <b>61958-2501-01</b>	CustomerPO #: <b>-</b>
	Document Type: <b>Invoice</b>
	Reference Date: <b>4/7/2021</b>

LOT # 021350	QUANTITY 3	E XP DATE 02/23
LOT # CFHKHA	QUANTITY 1	EXP DATE 03/23
LOT # 022056	QUANTITY 1	E XP DATE 12/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTION</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;  
(B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;  
(C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;  
(D) did not knowingly ship a suspect or illegitimate product;  
(E) had systems and processes in place to comply with verification requirements under section 582;  
(F) did not knowingly provide false transaction information; and  
(G) did not knowingly alter the transaction history.

# Drug Supply Chain Security Act Document Doc#00000024031

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>	ReferenceNumber: <u><b>5599</b></u>
NDC: <b>61958-2501-01</b>	CustomerPO #: <u>-</u>
	Document Type: <u><b>Invoice</b></u>
	Reference Date: <u><b>4/7/2021</b></u>

LOT # 021345	QUANTITY 3	EXP DATE 02/23
LOT# CFBGMA	QUANTITY 1	EXP DATE 03/23
LOT # 022055	QUANTITY 1	EXP DATE 12/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer's information: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR</b> <b>TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH</b> <b>COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21612</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address <b>822 CAMBRIDGE, MD 21613:</b> Date Received & Ref : <b>4/8/21 1468</b>

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.



# Drug Supply Chain Security Act Document Doc#00000024032

## (TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size: <b>Biktarvy 50mg/200mg/25mg Tablet, 30 EA</b>		ReferenceNumber: <u>5599</u>
NDC: <b>61958-2501-01</b>		CustomerPO #: <u>-</u>
		Document Type: <u>Invoice</u>
		Reference Date: <u>4/7/2021</u>

LOT # 023252	QUANTITY 3	EXP DATE 02/23
LOT #022614	QUANTITY 1	EXP DATE 03/23
LOT # CDSFBA	QUANTITY 1	EXP DATE 12/22

## (TH) Transaction History

Manufacturer's Name: **GILEAD SCIENCES, INC**  
Manufacturer'sinformation: **Foster City, CA 94404**

<b>SOLD TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR TUKWILA, WA 98188</b> Date Purchased & Ref : <b>3/16/2021 1172633</b>	<b>SHIPPED TO:</b> Name: <b>INVICTA WHOLESALE SUPPLY (LIC: 60706408)</b> Address: <b>1126 INDUSTRY DR TUKWILA, WA 98188</b> Date Received & Ref : <b>3/16/2021 1172633</b>
---	---

<b>SOLD TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH COALING, AL 35453</b> Date Purchased & Ref : <b>4/7/2021 5599</b>	<b>SHIPPED TO:</b> Name: <b>CM PHARMACEUTICAL LLC (LIC: 194900)</b> Address: <b>15329 HIGHWAY 11 NORTH COALING, AL 35453</b> Date Received & Ref : <b>4/7/2021 5599</b>
--	--

<b>SOLD TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Purchased & Ref : <b>4/8/21 1468</b>	<b>SHIPPED TO:</b> Name: <b>SAFE CHAIN SOLUTIONS</b> Address: <b>822 CAMBRIDGE, MD 21613</b> Date Received & Ref : <b>4/8/21 1468</b>
--	--

<b>SOLD TO:</b> Name: Address:  Date Purchased & Ref :	<b>SHIPPED TO:</b> Name: Address:  Date Received & Ref :
--	--

## (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.